Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial

Br J Dermatol. 2024 Aug 31:ljae343. doi: 10.1093/bjd/ljae343. Online ahead of print.

¹ Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
² Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
³ Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.

No abstract available